Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Regina Garcia Delgado, Dunia de Miguel, Alicia Bailen, José Ramón Gonzalez, Joan Bargay, Jose F Falantes, MD, Rafael Andreu, Fernando Ramos, Mar Tormo, Rafael F Duarte, MD, PhD, Ma José Jiménez Lorenzo, Salut Brunet, Benet Nomdedeu, Antonio Figueredo, Javier Casaño, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Blood (2012) 120 (21): 1710.

https://doi.org/10.1182/blood.V120.21.1710.1710

Published: 2012

Journal Articles

Analysis of Spanish Experience During Imiglucerase Shortage

Pilar Giraldo, PhD, Pilar Irún, PhD, Pilar Alfonso, PhD, Jaime Dalmau, MD, MAngeles Fernández-Galán, MD, Antonio Figueredo, MD, Angela Ibañez, MD, Jesús M Hernández-Rivas, PhD, Elisa Luño, MD, Francisca Marín-Jimenez, Guillermo Martin-Nuñez, MD, Jorge Montserrat, MD, Javier De la Serna, MD, PhD, Lucia Villalon, MD, Miguel Pocovi, PhD

Blood (2010) 116 (21): 4725.

https://doi.org/10.1182/blood.V116.21.4725.4725

Published: 2010

Journal Articles

Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, Dunia de Miguel, MD, Alicia Bailen, MD, José Ramón González, MD, PhD, Guillermo Sanz, Jose F Falantes, MD, Rafael Andreu, MD, Mar Tormo, MD, Rafael F Duarte, Antonio Figueredo, MD

Blood (2009) 114 (22): 2773.

https://doi.org/10.1182/blood.V114.22.2773.2773

Published: 2009

Journal Articles

Azacitidine Is Effective in Patients with Low / Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry.

Regina Garcia, MD, Dunia de Miguel, MD, Maria-Teresa Bernal, MD, Mar Tormo, MD, Guillermo Sanz, Raquel de Paz, MD, PhD, Antonio Figueredo, MD, Maria E Amutio, MD, José L. Guzmán, MD

Blood (2009) 114 (22): 3801.

https://doi.org/10.1182/blood.V114.22.3801.3801

Published: 2009

Journal Articles

Azacitidine Is Effective in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, Dunia de Miguel, MD, Alicia Bailen, MD, Jose Ramon Gonzalez, MD, PhD, Rafael Andreu, MD, Mar Tormo, MD, Jose F Falantes, MD, Guillermo Sanz, Rafael F Duarte, Antonio Figueredo, MD

Blood (2009) 114 (22): 4836.

https://doi.org/10.1182/blood.V114.22.4836.4836

Published: 2009

NARROW

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Analysis of Spanish Experience During Imiglucerase Shortage

Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.

Azacitidine Is Effective in Patients with Low / Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry.

Azacitidine Is Effective in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Email alerts

ASH Publications

American Society of Hematology

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Analysis of Spanish Experience During Imiglucerase Shortage

Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.

Azacitidine Is Effective in Patients with Low / Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry.

Azacitidine Is Effective in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only